The last steps of bacterial peptidoglycan synthesis are performed by a set of membrane-bound enzymes, the penicillinbinding proteins (PBPs) (12) . These enzymes are irreversibly inactivated by ␤-lactam antibiotics, thus leading to cell death. Escherichia coli has nine PBPs, which fall into two groups. The low-molecular-weight PBPs (PBP4 to -7) are endopeptidases or carboxypeptidases, while the high-molecular-weight PBPs are transpeptidases (PBP2 and -3) or both transpeptidases and transglycosylases (PBP1a and -1b) (1, 17, 19, 29, 38, 40) . These latter enzymes are thought to be organized into two domains, the N-terminal domain harboring the transglycosylase activity and the C-terminal domain harboring the transpeptidase activity. PBP1a and -1b can mutually complement each other, but PBP1b seems to be much less sensitive to antibiotics than PBP1a (42) . PBP1b is found as three polypeptides; ␣ and ␥ arise from two different translation initiations of the ponB mRNA, while ␤ is a degradation product of ␣ (39) .
From sequence alignments of various PBPs, the boundary between the transglycosylase and transpeptidase domains has been roughly defined, as have some conserved motifs (13) . These data have been complemented by results of a number of deletion experiments (22, 30, 31) . Using random fusions with ␤-lactamase, Edelman et al. (10) have shown that PBP1b is anchored into the cytoplasmic membrane, residues 88 to 844 being periplasmic. Several attempts to solubilize PBP1b by fusing the periplasmic domain to a secretion signal peptide have nonetheless proved unsuccessful (37) . It has been hypothesized that another domain of interaction between the protein and the cytoplasmic membrane, apart from the N-terminal anchor, may exist (5, 33) . Den Blaauwen et al. (6) (7) (8) used monoclonal antibodies raised against four antigenic determinants of PBP1b to study the membrane topology, spatial organization, and enzyme activities of this protein. They deduced that PBP1b could be organized as a globular protein with two intimately associated enzymatic domains. The structure of PBP2x from Streptococcus pneumoniae has recently been solved (34) and can be used along with the sequence alignments to define more precisely the topology of the transpeptidase domain of PBP1b. This information is still partial and lacks experimental support, especially concerning the reported conserved motifs and the domain boundaries.
We have used alanine stretch scanning (ASS) to sequentially explore the topology of PBP1b. ASS consists of the introduction of a stretch of alanine residues within a specific sequence of the protein, either as an insertion or as a substitution. This method yields structural and functional information on the role of the residues where the stretch has been introduced (25) . We used a five-alanine stretch substitution to scan the sequence of PBP1b (Fig. 1a) . The positions of the substitutions were chosen to probe the functional role of residues derived from sequence alignments, or to define domain boundaries, either for the transglycosylase and transpeptidase domains, for the C terminus, or for the transmembrane domain.
MATERIALS AND METHODS
Media and growth conditions. Cultures were grown in LB medium (1% tryptone [Difco Laboratories, Detroit, Mich.], 0.5% yeast extract [Difco], 1% NaCl) at 37°C. When necessary, tetracycline (12.5 g/ml; Boehringer Mannheim, Germany), spectinomycin (100 g/ml; Sigma, St. Louis, Mo.), kanamycin (50 g/ml; Sigma), or chloramphenicol (30 g/ml; Serva, Heidelberg, Germany) was added.
Bacterial strains and plasmids. The E. coli K-12 strains used were MC6-RP1 (F Ϫ thrA leuA proA lysA dra drm), QCA2 (F Ϫ thrA leuA proA lysA dra drm ⌬ponA::Km r ), and QCB1 (F Ϫ thrA leuA proA lysA dra drm ⌬ponB::Spc r ). Cloning steps were performed with MC1061 [F Ϫ araD139 ⌬(ara-leu)7636 galE15 galK16
. Plasmid pAB (35) was used for SecB chaperone coexpression. Plasmids pBR322 and pACYC184 were used for construction steps. Plasmid pHK2414 bearing the ponB gene was provided by W. Keck, and plasmid pGTEPI bearing the sequence of the influenza virus hemagglutinin HA1 epitope was provided by B. Nefsky.
Cloning procedures. All cloning steps were carried out as described by Maniatis et al. (28) . All restriction and modification enzymes were purchased from New England Biolabs (Beverly, Mass.) and used according to the manufacturer's recommendations. Competent cells were prepared and transformed as described by Hanahan (15) .
Construction of plasmid pPONB, expressing the ponB gene. After the introduction by site-directed mutagenesis of an EcoRI site on the TAG stop codon of the ponB gene (on plasmid pHK2414), the gene was excised by EcoRI/EcoRV digestion. This fragment was ligated with the DraI/AvaI fragment of pBR322 bearing the origin of replication, the BstBI/AvaI fragment of pACYC184 bearing the tetracycline resistance gene, and the PCR-amplified EcoRI/ClaI fragment of pGTEPI bearing the antigenic determinant from the influenza virus hemagglutinin HA1 epitope. The result is a moderate-copy-number plasmid of 6,155 bp, pPONB (Fig. 1b) . This plasmid confers tetracycline resistance and allows expression of the PBP1b protein fused to a peptide tag. All PstI and PvuII sites of this plasmid were subsequently eliminated by site-directed mutagenesis. The ponB gene was sequenced to confirm the absence of any secondary mutation. We found that the wild-type sequence of codons 102 and 103 is CTG CCT (Leu Pro) instead of CTC GCT (Leu Ala) as described by Broome-Smith et al. (3) .
Site-directed mutagenesis and oligonucleotides. Double-strand mutagenesis was performed as described by Deng and Nickoloff (9) . The eight ASS mutants were constructed as described by Lefèvre et al. (25) . ASS oligonucleotides were synthesized by Isoprim (Toulouse, France). All mutations were checked by sequencing at Genome Express (Grenoble, France). To construct the C-terminal deletion of the ASS 1 mutant, the plasmid bearing the ASS 1 mutation was digested with the EcoRI and PstI endonucleases and ligated with a singlestranded oligonucleotide of 11 bases.
Software. DNA and protein sequences were analyzed and aligned by using PCGENE. Secondary structures of PBP1b were predicted by hydrophobic clusters analysis using the HCA program (26) . Antibiotic susceptibility. Bacteria expressing the PBP1b variants were assayed for growth in the presence of various antibiotics by using the disc agar diffusion method (27) . Each of the antibiotic paper discs was saturated with 6 g of penicillin G, 25 g of amoxicillin, 75 g of ticarcillin, 30 g of aztreonam, 10 g of mecillinam, 30 g of cefotaxime, or 30 g of cefalotine.
Preparation of the membrane fraction and labeling of the PBPs with fluorescent penicillin. E. coli QCB1 expressing wild-type PBP1b or any of its variants was grown in LB medium. Cells were harvested during the exponential growth phase (A 600 ϭ 1) by centrifugation at 6,000 ϫ g for 15 min. Membrane extraction was done as described by Lakaye et al. (24) , and extracts were stored at Ϫ20°C at a final protein concentration of 25 to 30 mg/ml as quantified by the Bradford method (2).
Fluorescent 6-amino-penicilloic acid (6-APA-FLU) was synthesized as described by Galleni et al. (11) and Lakaye et al. (24) . The absence of free unlabeled penicillin at the end of the purification step was confirmed by mass spectrometer analysis (MALDI) of 6-APA-FLU. Labeling of PBPs was done by mixing 4 l of membrane extract with 2 l of 6-APA-FLU at 147 g/ml and 14 l of sodium phosphate buffer (50 mM, pH 7.0) to obtain a 20-l sample. This sample was incubated 30 min at 30°C. The same protocol, without 6-APA-FLU, was used for the immunodetection of the PBPs with antibody 12CA5.
Electrophoresis and immunodetection. Samples (20 l) were denatured at 95°C for 5 min in a sodium dodecyl sulfate-urea-␤-mercaptoethanol buffer and analyzed by electrophoresis on a sodium dodecyl sulfate-homogeneous 7.5% polyacrylamide gel as described by Laemmli (23) . Gels were transferred to nitrocellulose membranes (Hybond-C; Amersham) in a semidry apparatus (4). Membranes were incubated with an antifluorescein horseradish peroxidase conjugate (1/500) (when PBPs had previously been labeled with 6-APA-FLU) or with antibody 12CA5 (1/1,000) (raised against the HA1 peptide tag from the hemagglutinin of influenza virus), and with an anti-mouse peroxidase conjugate (1/5,000; Sigma).
RESULTS
In vivo production and activity of cloned PBP1b. To detect the production of PBP1b, we added a peptide tag at the C terminus of the protein. We used a short nine-amino-acid sequence (YPYDVPDYA) from the hemagglutinin HA1 epitope of influenza virus that contains a complete antigenic determinant (41) . Figure 2 shows that the tagged PBP1b expressed from the pPONB plasmid is readily detected by Western blotting. In vivo activities of this modified PBP1b and its mutants were assayed by antibiogram disc assays ( Table 1) . The wild-type strain MC6RP1 is resistant to penicillin G but sensitive to various extents to all of the other ␤-lactam antibiotics. While deletion of PBP1a in strain QCA2 has a minor effect on antibiotic sensitivity, deletion of PBP1b in strain QCB1 results in a marked increase of all inhibition diameters. This is true even for mecillinam, which has been shown to inhibit specifically PBP2. Expression of the tagged PBP1b from vector pPONB in QCB1 restores wild-type values.
Since cefaloridine inhibits PBP1a much more efficiently than PBP1b (42) , it was used to overcome the complementation effect between these two PBPs. While adding cefaloridine (0.3 g/ml) to the medium has little effect on the antibiotic sensitivity of wild-type strain MC6RP1 or QCA2, it very efficiently inhibits growth of QCB1. The mutant strain harboring pPONB is overall slightly less sensitive than the wild type to ␤-lactam antibiotics on cefaloridine plates.
Penicillin-binding activity was assayed with a fluorescein derivative of penicillin (6-APA-FLU), which can be detected by an enhanced chemiluminescence immunodetection technique using an antifluorescein antibody. While wild-type MC6RP1 extract clearly shows two bands corresponding to PBP1a and PBP1b (Fig. 3) , only PBP1a can be detected in QCB1. Strain QCB1 harboring pPONB overexpresses PBP1b, resulting in a strong labeling with 6-APA-FLU. The modified PBP1b overexpressed from plasmid pPONB is thus able to fully complement the deletion of the ponB gene in strain QCB1 and does not alter cell growth (Table 1) .
Scanning the C-terminal domain. It has been shown that the last 65 residues of PBP1b (M 780 to N 844 ) are dispensable for its in vivo activity (21, 22) . On the other hand, the penicillininteracting domain is assumed to end 60 residues downstream from the KTG motif (14) , i.e., at residue V 758 . Mutant ASS 1 was constructed by substituting residues D 762 to M 766 by alanines (Fig. 1a) . Strain QCB1 transformed with the mutated plasmid exhibits the same antibiogram pattern as the wild-type strain MC6RP1 or strain QCB1 transformed with the wild-type pPONB (Table 1) . Adding cefaloridine to the medium at a concentration that fully inhibits PBP1a activity does not modify significantly this antibiogram pattern, suggesting that mutant ASS 1 is fully functional. Indeed, the mutant protein is detected both by Western blotting with the antitag antibody ( Fig.  2) and by fluorescent penicillin binding (Fig. 4 ), albeit to a lower level than the wild type.
The next step was to delete this C-terminal portion of the gene, by fusing the D 762 codon directly to the tag sequence. This construct, called the C-term mutant, yields an antibiogram pattern similar to that of strain QCB1 alone. Cefaloridine readily kills the cells expressing the C-term mutant, as it does with QCB1. Thus, this mutant does not complement at all the PBP1b deletion and PBP1a inhibition. The deleted protein is produced in the cells at the same level as mutant ASS 1 (Fig.  2) , but no penicillin binding can be detected (data not shown).
A second mutant was then made in the C-terminal region by replacing residues N 773 to S 777 by alanines. This mutant, named ASS 8, is as active as the wild-type PBP1B when expressed in QCB1 (Table 1) , and the cells grow just as well with cefaloridine in the plates. Indeed, the mutant protein is produced at wild-type levels ( Fig. 2 ) and binds fluorescent penicillin (Fig. 4) , which confirms that these residues are not important for the protein activity.
Scanning the transpeptidase and transglycosylase domains borders. To study the structure of PBP1b or some of its domains, it is first necessary to define the limits of these domains. In ASS 5, residues V 99 to P 103 are substituted by alanine, to see how far down the N-terminal sequence the transglycosylase domain extends. Several previous experiments indicate that the transmembrane domain of PBP1b probably includes residues 64 to 87 (7, 10) . The N-terminal border of the transglycosylase domain has been determined to be located at residue 185 by sequence alignments (13) . This would leave quite a large peptide with an as yet undefined role. Locating our mutation rather far from this hypothetical border was expected to yield minimal perturbation to the functions of PBP1b. However, the in vivo activity of the mutant ASS 5 is reduced, as seen from the inhibition diameters of the transformed QCB1 strain, which are intermediate between the values obtained with the wild-type strain MC6RP1 and those obtained with the PBP1b deletion mutant QCB1. If the cells are grown with 0.3 g of cefaloridine per ml, inhibition diameters with the other antibiotics are significantly increased, showing that mutant ASS 5 only partially complements the PBP1b deletion and the PBP1a inhibition. The mutant protein is produced at the same level as the wild type (Fig. 2) and strongly binds fluorescent penicillin (Fig. 4) . Although this alanine stretch was introduced in a region without known function, it affects peptidoglycan synthesis activity to a certain extent but does not affect penicillin binding.
Alignment of the PBP1a and PBP1b sequences shows a 106-residue insertion in PBP1a, at the position of PBP1b residue 470 (3). Since both proteins have transglycosylase and transpeptidase activity, it was concluded that this insertion must lie between the two catalytic domains. Another sequence alignment placed the transpeptidase domain border at residue 460 (12) . On the other hand, C-terminal deletions down to residue 423 still yield an active transglycosylase (21, 30 2) and had a very low but detectable penicillin-binding activity (Fig. 4) . Thus, the low level of activity of this mutant is likely to be caused by degradation and/or improper membrane localization.
Since the low level of in vivo activity of mutant ASS 4 could be attributed to a production problem, we tried to produce the mutant enzyme in a QCB1 cell overexpressing the SecB chaperone from the pAB plasmid (35) . Under these conditions, the antibiotic sensitivity of QCB1 expressing the ASS 4 mutant is markedly reduced ( Table 2) .
On the transglycosylase side, we made mutant ASS 7, replacing residues G 427 to K 431 by alanines. The antibiogram 
a Numbers indicate growth inhibition diameters in millimeters. The antibiotics discs were 6 mm in diameter. Abbreviations: PG, penicillin G; AMX, amoxicillin; TIC, ticarcillin; MEC, mecillinam; CF, cefalotine; CTX, cefotaxime; ATM, aztreonam; ϪCD and ϩCD, growth in medium not containing and containing cefaloridine at 0.3 g/ml; R (resistant), bacteria grew at the border of the antibiotic disc; S (sensitive), only a few bacteria grew on the plates; D (death), no bacteria grew on the plates.
profile of strain QCB1 harboring this mutant is identical to that of the same strain expressing the wild-type PBP1b encoded by the pPONB plasmid (Table 1) . Adding cefaloridine to the plates has no impact on its antibiogram profile. The mutant protein is well produced (Fig. 2) and binds fluorescent penicillin as well as the wild-type enzyme (Fig. 4) . The mutation has no impact on the in vivo or in vitro activity of PBP1b, thus confirming that it is probably located outside both the transglycosylase and the transpeptidase domains.
Transpeptidase activity variants. The transpeptidase domain of PBPs probably has some homology with the class A ␤-lactamases, since ␤-lactam antibiotics are suicide inhibitors of the former and substrates of the latter. Sequence alignments pointed to serine 510 of PBP1b as the equivalent of the catalytic residue serine 70 in class A ␤-lactamases, a hypothesis confirmed by acylation of this residue with 14 C-penicillin G (32) . We made the ASS 2 mutation around position 510, as a control for our mutagenesis method. This mutation was expected to yield an inactive mutant without perturbing the production of the protein, if the catalytic serine is on an ␣ helix as in ␤-lactamases. This protein is produced at a high level (Fig.  2) , but the antibiogram pattern of strain QCB1 expressing this mutant is identical to that of strain QCB1 alone, thus showing that overproducing an inactive mutant does not modify the antibiograms. Moreover, no fluorescent penicillin binding was detected with this mutant protein (Fig. 4) .
The SXN motif plays a major role in the catalytic activity of ␤-lactamases. Ghuysen and Dive (13) suggested that an SGR motif at positions 560 to 562 in PBP1b may replace the SXN sequence. To test this hypothesis, we constructed mutant ASS 3, where alanines replace residues S 558 to R 562 . This mutant is fully active in vivo (Table 2 ) and complements both the ponB deletion and the PBP1a inhibition in strain QCB1. It is produced to a correct level and binds fluorescent penicillin as efficiently as the wild-type protein ( Fig. 2 and 4) . This result clearly rules out the SGR motif as an equivalent of the SXN of class A ␤-lactamases.
While this work was in progress, the structure of S. pneumoniae PBP2x was published (34) . Comparison of the PBP2x structure with that of class A ␤-lactamases and sequence alignment with the transpeptidase domain of PBP1b suggested that another good candidate for the SXN motif in PBP1b could be S 572 M 573 N 574 . We therefore made mutant ASS 6, where residues S 572 to T 577 are replaced by alanines. The QCB1 strain expressing mutant ASS 6 has an antibiotic profile identical to that of strain QCB1 alone except that it is even more sensitive to mecillinam and is readily killed by cefaloridine. Although the mutant protein is correctly produced (Fig. 2) , it does not bind fluorescent penicillin (Fig. 4) . The behavior of mutant ASS 6 is in fact identical to that of mutant ASS 2, where an essential catalytical residue has been substituted.
DISCUSSION
We have developed simple assays to detect the in vivo and in vitro activities of PBP1b variants. The antibiotic disc assay of the ⌬ponB QCB1 strain expressing these variants is a sensitive in vivo test of protein activity. The total inhibition of PBP1a by cefaloridine at 0.3 g/ml reveals the specific peptidoglycan synthesis activity of the PBP1b variants. Finally, the use of 6-APA-FLU to probe the penicillin-binding activities of the variants turns out to be a quick and efficient in vitro test of the transpeptidase domain activity.
Use of alanine-stretch mutagenesis to scan a protein sequence yields several types of interesting results. Secondary structure predictions can be checked very easily, as an alanine stretch has a propensity to fold into helices or loops but tends to disrupt ␤ sheets. Surface areas of the protein should be more amenable to such substitutions, while thermosensitive phenotypes and folding mutants will arise from substitutions in the core. This strategy can be used to search for mutants with novel in vivo and in vitro characteristics. Substitution by an alanine stretch can also be used to investigate protein-protein interactions and can be especially useful for epitope mapping or to find permissive sites for insertion of foreign epitopes in a protein. Scanning of PBP1b by the ASS method was particularly efficient for detecting key positions in the protein.
Residues 762 to 780 are not dispensable. The behavior of the C-terminal tail is quite interesting. Strain QCB1 expressing mutant ASS 1 (D 762 to M 766 ) exhibits the same antibiogram pattern as wild-type strain MC6RP1, while deletion of this C-terminal portion of PBP1b inactivates the protein. This result was quite surprising, since it has been shown that the C-terminal residues down to M 780 are not required for the in vitro activity of PBP1b (21, 22) . We thought that some of the (10) suggested that PBP1b is embedded in the cytoplasmic membrane by a single hydrophobic transmembrane segment (residues 64 to 87), with a short N-terminal domain (residues 1 to 63), the remainder of the polypeptide (residues 88 to 844) being exposed on the periplasmic side of the cytoplasmic membrane. These results have been confirmed by the experiments of Den Blaauwen et al. (7), who observed that no monoclonal antibody raised against the G 64 -to-G 84 segment could be obtained. To solubilize PBP1b, it would be necessary to introduce a signal peptide sequence, downstream from the end of the hydrophobic helix and upstream from the beginning of the transglycosylase domain. Mutant ASS 5 (V 99 to P 103 ) was created close to the transmembrane helix. Its in vivo behavior clearly demonstrates that this mutant is not as efficient as the wild-type protein in complementing the PBP1b deletion. Had this mutation modified the folding of the protein, a more drastic antibiotic effect would have been observed when PBP1a was inhibited by cefaloridine. Moreover, detection of this mutant by immunoblotting implies that a correct folding had occurred, since the misfolded protein would have been degraded. Finally, the penicillin-binding activity of mutant ASS 5 is consistent with its proper folding. The weak in vivo activity of mutant ASS 5 may be due to an altered transglycosylase region, but this is unlikely for several reasons. Ghuysen and Dive located the border of the transglycosylase domain by sequence alignment (13) at residue N 185 , far from the ASS 5 mutation. Sequence alignments of the transglycosylase domain of PBP1b with the monofunctional transglycosylase (36) shows that the first highly conserved motifs are located upstream from the L 230 residue. Moreover, HCA modeling predicts an ␣-helix structure from residues A 73 to M 110 . The ASS 5 mutation should not change the structure, but alanine substitution could have modified side chain interactions, thus altering the position of the catalytic sites with respect to their substrates. Nonetheless, analysis of this mutant clearly indicates that the junction between the hydrophobic helix and the transglycosylase domain is involved in the in vivo activity of PBP1b.
Functional motifs of the transpeptidase domain. Serine 510 is the acylated residue of PBP1b during the transpeptidation reaction. It is part of a highly conserved sequence (SXXK) of PBPs and class A ␤-lactamases. Sequence alignments with PBP2x from S. pneumoniae suggested that the SXXK box is located in an ␣-helical region (35) . We have used mutant ASS 2 (S 510 to P 514 ) as a positive control of our mutagenesis approach. This mutant yielded a protein totally devoid of in vivo activity. This protein is produced at the same level as the wild type, which tends to prove that it does not encounter any folding problems, and we can therefore suppose that its transglycosylase domain remains active. As expected, this protein had no penicillin-binding activity, since alanine substitution of the SXXK box has specifically inactivated the transpeptidase domain. Moreover, the marked susceptibility to all antibiotics of strain QCB1 expressing mutant ASS 2 shows that PBP1b is the major transpeptidase enzyme involved in the peptidoglycan synthesis. This is perfectly in line with the natural susceptibility of the ⌬ponB QCB1 strain.
The SXN box is part of the active site of ␤-lactamases. The asparagine interacts with the omega loop, and the serine is involved in the catalytic process (20) . This box is also observed in various PBPs by sequence analysis. Analysis of mutant ASS 3 proves that the SGR pattern, contrary to the proposition of Ghuysen and Dive (13), does not take part in the transpeptidase activity of PBP1b. Another SXN pattern that could be investigated was S 572 M 573 N 574 . This motif lies between the SXXK box and the only possible KTG pattern (another conserved box) found by sequence alignment with other PBPs. Analysis of mutant ASS 6 (substituting the S 572 -to-T 577 stretch), which yields a PBP1b that has no penicillin-binding activity, confirms the suspected central role of this SXN box in the transpeptidase mechanism. We can therefore conclude that the characteristic penicilloyl serine transferase motifs of PBP1b are S 510 L 511 A 512 K 513 , S 572 M 573 N 574 , and K 698 T 699 G 700 .
Permissive junction between the transpeptidase and transglycosylase domains. The boundary between the transpeptidase and transglycosylase domains is still undetermined. Sequences alignment and deletion analysis localized this junction between residues Q 423 and L 470 . The first attempt to define this limit was made with mutant ASS 4 (G 471 to V 475 ) at the N-terminal border of the transpeptidase domain. This mutation leads to a weakly produced protein. The in vivo activity of this PBP1b variant is not able to compensate for the complete inhibition of PBP1a by cefaloridine. The positive effect of the coexpression of the SecB chaperone suggests that mutant ASS 4 encounters folding problems. This is perfectly in line with the HCA predictions and with the sequence alignment with the PBP2x of S. pneumoniae, which suggest that the region from A473 to F480 is structured as a ␤ sheet that would be disrupted by the mutation. We then moved the mutation to positions G427 to K431, a region predicted to fold as an ␣ helix by HCA modeling. This new variant, ASS 7, yields a fully active protein both in vivo and in vitro. These results demonstrate that a polyalanine substitution can be carried out between the transpeptidase and transglycosylase domains without any loss of the in vivo activity (and of the in vitro penicillin-binding activity). This junction seems to be a permissive insertion site as described by Hofnung et al. (18) . Finding this junction is crucial for further attempts to separate the transpeptidase from the transglycosylase domain. At present, experiments are in progress to investigate this possibility, and we have already demonstrated that the insertion of 10 amino acids at this position does not alter the in vivo activity of the protein.
